Página principal2269 • HKG
add
WuXi Biologics (Cayman) Inc
Cierre anterior
$14.58
Intervalo del día
$14.16 - $14.74
Intervalo anual
$12.42 - $52.45
Cap. bursátil
62.46 mil M HKD
Volumen prom.
45.66 M
Relación precio‑beneficio
17.31
Rendimiento por dividendos
-
Mercado primario
HKG
Noticias del mercado
Finanzas
Estado de ingresos
Ingresos
Ingresos netos
| (CNY) | dic 2023info | Cambio interanual |
|---|---|---|
Ingresos | 4271.10 M | 5.95% |
Gastos de operación | 818.44 M | 13.31% |
Ingresos netos | 566.53 M | -39.90% |
Margen de utilidad neta | 13.26 | -43.28% |
Ganancias por acción | — | — |
EBITDA | 1064.06 M | -1.78% |
Tasa impositiva vigente | 25.05% | — |
Balance general
Activos totales
Pasivos totales
| (CNY) | dic 2023info | Cambio interanual |
|---|---|---|
Inversiones plazo/efectivo | 11.24 mil M | 29.02% |
Activos totales | 56.58 mil M | 14.15% |
Pasivos totales | 12.56 mil M | -5.94% |
Acciones totales | 44.02 mil M | — |
Acciones en circulación | 4222.73 M | — |
Precio/valor contable | 1.53 | — |
Rendimiento de los activos | 3.60% | — |
Rendimiento del capital | 4.19% | — |
Flujo de efectivo
Variación neta en caja
| (CNY) | dic 2023info | Cambio interanual |
|---|---|---|
Ingresos netos | 566.53 M | -39.90% |
Efectivo de operaciones | — | — |
Efectivo de inversiones | — | — |
Efectivo de financiación | — | — |
Variación neta en caja | — | — |
Flujo de efectivo libre | — | — |
Acerca de
WuXi Biologics is a global Contract Research Development and Manufacturing Organization that provides open-access, integrated technology platforms for biologics drug development.
WuXi Biologics' roots date back to 2010, and began building out capabilities and facilities required for biologics discovery, development and GMP manufacturing. WuXi Biologics went public on the Hong Kong Stock Exchange in June 2017.
As of 2021, WuXi Biologics has 18 manufacturing sites including ten in China, three in the United States, two in Ireland, two in Germany, and one in Singapore.
In August 2020, WuXi Biologics was selected to become a component of the Hang Seng Index in Hong Kong.
In January 2024, WuXi Biologics' share price fell on news that the United States Congress had introduced legislation to block any federal government contracts with the company due to national security concerns. The concerns stem from allegations, denied by the company, that it has worked closely with the People's Liberation Army as a part of the Chinese Communist Party's military-civil fusion strategy. Wikipedia
Director general
Fecha de fundación
2010
Sitio web
Cantidad de empleados
12,740
